A Look At Idexx Laboratories (IDXX) Valuation After Earnings Beat, Outlook Upgrade And Product Expansion

Simply Wall St.06-06

AdvertisementIDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight IDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641144414?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/29729-main-header/1756252961457","is_english":true,"pubTime":"2026-06-06 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641144414","market":"sg","top_or_hot":-1,"title":"A Look At Idexx Laboratories (IDXX) Valuation After Earnings Beat, Outlook Upgrade And Product Expansion","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementIDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight IDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/a-look-at-idexx-laboratories-idxx-valuation-after-earnings-b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Idexx Laboratories (IDXX) Valuation After Earnings Beat, Outlook Upgrade And Product Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Idexx Laboratories (IDXX) Valuation After Earnings Beat, Outlook Upgrade And Product Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-06 01:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/a-look-at-idexx-laboratories-idxx-valuation-after-earnings-b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementIDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight IDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/a-look-at-idexx-laboratories-idxx-valuation-after-earnings-b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDXX","symbol_name":"爱德士实验室","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/a-look-at-idexx-laboratories-idxx-valuation-after-earnings-b","article_id":"2641144414","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/29729-main-header/1756252961457"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/a-look-at-idexx-laboratories-idxx-valuation-after-earnings-b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641144414","pubTimestamp":1780680899,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight\nIDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings and revenue beat, an upgraded 2026 outlook, and a fresh expansion of its Fecal Dx parasite testing platform.\nSee our latest analysis for IDEXX Laboratories.\nThe recent earnings beat, upgraded 2026 outlook, and broader Fecal Dx parasite menu come after a period where the share price has eased, with the 90 day...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"IDXX":"爱德士实验室"},"translate_title":"Idexx Laboratories(IDXX)盈利超出预期、前景升级和产品扩张后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDXX":1.5},"content_text":"AdvertisementIDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight IDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings and revenue beat, an upgraded 2026 outlook, and a fresh expansion of its Fecal Dx parasite testing platform. See our latest analysis for IDEXX Laboratories. The recent earnings beat, upgraded 2026 outlook, and broader Fecal Dx parasite menu come after a period where the share price has eased, with the 90 day share price return down 7.18% and the year to date share price return down 15.71%, even as the 1 year total shareholder return is 8.14%, which hints at longer term holders still being in positive territory. If this kind of diagnostics story interests you, it can be useful to see what else is shaping healthcare and pet care, including companies using AI in medicine, through our 40 healthcare AI stocks. The stock has eased in recent months, even though earnings, revenue, and guidance have all exceeded expectations. Are you looking at an underappreciated diagnostics leader, or has the market already fully reflected its growth story in the price? Most Popular Narrative: 25% Undervalued The most followed narrative sees IDEXX Laboratories trading below an implied fair value of $750.23 compared with the last close of $564.74, and ties that gap to recurring diagnostics growth and margin assumptions.  Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.  Read the complete narrative. Want to understand why this narrative treats a premium P/E and high margins as achievable, not aspirational? The entire case leans on recurring diagnostics, richer software revenue, and a specific glide path for earnings and share count. Curious which assumptions really carry the $750.23 fair value and how much growth is baked into that gap versus today’s price? Result: Fair Value of $750.23 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on clinic visit trends and international adoption not slowing more than expected, and on competitors not chipping away at pricing power or recurring diagnostics demand. Find out about the key risks to this IDEXX Laboratories narrative. Another Angle On Price: Earnings Multiple Looks Stretched That 25% undervalued fair value hinges on long term cash flows, but the current P/E of 40.7x tells a different story. It sits well above the peer average of 26.4x and a fair ratio of 28.5x, which points to meaningful valuation risk if sentiment or growth expectations cool from here. For a closer look at how this valuation gap could matter for your own expectations, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:IDXX P/E Ratio as at Jun 2026Next Steps Given the mix of optimism and concern running through this story, it makes sense to move quickly and test the numbers yourself, then weigh the 4 key rewards and 1 important warning sign Looking for more investment ideas? If IDEXX has sharpened your focus, do not stop here. Broaden your watchlist with curated stock ideas that could suit different risk levels and return goals.  Target value opportunities by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that may sit below their implied worth. Strengthen your defensive side by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair healthy finances with underlying business resilience. Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems before others spot them and pricing expectations shift.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641144414","isCrawlerRequest":true}